John Connolly

John Connolly has a wealth of experience in the field of biomedical research. John began their career in 2009 as an Adjunct Associate Professor at Baylor University, and then served as Director for Research Initiatives at Baylor Research Institute in the same year. In 2011, they took on the role of Director for A*STAR Horizontal Program in Infectious Disease at A*STAR Biomedical Research Council. John then moved on to become a Senior Principal Investigator and Director for Translational Immunology at the Institute of Molecular and Cell Biology in 2010. In 2016, they began working as a Clinical Scientist at KK Women's & Children's Hospital, Associate Professor at National University of Singapore, Chief Scientific Officer at Tessa Therapeutics Pte Ltd, and Adjunct Associate Professor at Nanyang Technological University, Lee Kong Chian School of Medicine. Most recently, they took on the roles of Interim CEO at 3T Biosciences and Chief Scientific Officer at Parker Institute for Cancer Immunotherapy in 2020.

John Connolly obtained their Ph.D. in Biochemistry from the Geisel School of Medicine at Dartmouth between 1995 and 2001. Prior to that, they obtained a B.Sc in Chemistry and Biology from Framingham State University between 1989 and 1994.